⌕
Revolution Medicines · RVMD · Nasdaq
Tenet 39 · Weak
Compare
$162.69−2.50%At closeTenet 39 · Weak
$162.69−4.18 (−2.50%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
$163.55+0.86 (+0.53%)
After hours: Nov 17, 2026, 6:06 PM ET

Revolution Medicines (RVMD) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is RVMD's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Zacks Investment ResearchNov 17, 2026 · 14:16 ET
Revolution Medicines Wins EU Nod for Rasonque in Pancreatic Cancer

RVMD secures European Commission approval for Rasonque in metastatic pancreatic cancer, expanding its reach after a strong U.S. launch.…

RVMD −2.5% todayRead at source ↗
● GlobeNewsWireNov 16, 2026 · 13:00 ET
European Commission Approves Revolution Medicines' RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

REDWOOD CITY, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for …

RVMD −2.5% todayRead at source ↗
● Seeking AlphaNov 16, 2026 · 09:12 ET
Revolution Medicines, Inc. (RVMD) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Revolution Medicines, Inc. (RVMD) Presents at Jefferies Global Healthcare Conference 2026 Transcript…

RVMD −2.5% todayRead at source ↗
● Defense WorldNov 15, 2026 · 09:49 ET
Revolution Medicines, Inc. $RVMD Stock Acquired by Aberdeen Group plc

Aberdeen Group plc increased its holdings in shares of Revolution Medicines, Inc. (NASDAQ: RVMD) by 303.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commissio…

RVMD −2.5% todayRead at source ↗
● Defense WorldNov 13, 2026 · 04:39 ET
Chicago Partners Investment Group LLC Acquires New Position in Revolution Medicines, Inc. $RVMD

Chicago Partners Investment Group LLC acquired a new position in shares of Revolution Medicines, Inc. (NASDAQ: RVMD) during a recent quarter, according to its most recent 13F filing with the SEC. The firm acquired 2,941 …

RVMD −2.5% todayRead at source ↗
● Defense WorldNov 13, 2026 · 03:51 ET
Revolution Medicines, Inc. $RVMD Shares Sold by Alphabet Inc.

Alphabet Inc. trimmed its stake in Revolution Medicines, Inc. (NASDAQ: RVMD) by 9.3% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 2,673,909 shares of the company's stock …

RVMD −2.5% todayRead at source ↗
● Seeking AlphaNov 12, 2026 · 09:53 ET
Revolution Medicines: RASONQUE Is Off To A Strong Start, But Expectations Are High

Revolution Medicines has transitioned to commercial operations with a strong initial RASONQUE launch, generating $197.6M in five weeks post-FDA approval. RASONQUE's early demand is validated by over 5,000 unique U.S. pat…

RVMD −2.5% todayRead at source ↗
● Defense WorldNov 11, 2026 · 01:15 ET
Revolution Medicines (NASDAQ:RVMD) vs. Krystal Biotech (NASDAQ:KRYS) Head-To-Head Survey

Krystal Biotech (NASDAQ: KRYS - Get Free Report) and Revolution Medicines (NASDAQ: RVMD - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on th…

RVMD −2.5% todayRead at source ↗
● Seeking AlphaNov 10, 2026 · 11:01 ET
Revolution Medicines, Inc. (RVMD) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript

Revolution Medicines, Inc. ( RVMD ) 3rd Annual Guggenheim Healthcare Innovation Conference November 10, 2026 8:30 AM EST Company Participants Mark Goldsmith - CEO, President & Chairman Presentation Unknown Analyst Kick o…

RVMD −2.5% todayRead at source ↗
● Zacks Investment ResearchNov 10, 2026 · 10:56 ET
Wall Street Analysts Think Revolution Medicines (RVMD) Could Surge 33.34%: Read This Before Placing a Bet

The consensus price target hints at a 33.3% upside potential for Revolution Medicines (RVMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisio…

RVMD −2.5% todayRead at source ↗
● The Motley FoolNov 8, 2026 · 11:15 ET
Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy?

Its lead therapy is approved to treat previously treated patients with an advanced form of pancreatic cancer. The young drug company has a revolutionary pipeline of RAS-inhibitor therapies.…

RVMD −2.5% todayRead at source ↗
● The Motley FoolNov 8, 2026 · 10:15 ET
Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer Drug

Revolution Medicines' daraxonrasib has received FDA approval. Royalty Pharma estimates that the drug could produce peak revenues of $11 billion.…

RVMD −2.5% todayRead at source ↗
● Seeking AlphaNov 5, 2026 · 14:46 ET
Revolution Medicines Q3 Earnings: Stellar Company And Drug, But The Market Knows It

Revolution Medicines delivered $198M in Q3 revenue from RASONQUE's five-week U.S. launch, treating over 5,000 patients post-FDA approval. Despite strong early sales, RVMD's $40B valuation and high expectations temper fur…

RVMD −2.5% todayRead at source ↗
● Zacks Investment ResearchNov 5, 2026 · 14:21 ET
RVMD Q3 Earnings & Sales Beat Estimates on Encouraging Rasonque Uptake

Revolution Medicines' Q3 revenues beat estimates as Rasonque generated $197.6 million in just five weeks, signaling strong early launch demand.…

RVMD −2.5% todayRead at source ↗
● Defense WorldNov 5, 2026 · 01:15 ET
What Revolution Medicines (RVMD) Said on Its Q3 Earnings Call

Revolution Medicines (NASDAQ: RVMD) reported $197.6 million in third-quarter net product revenue from its newly approved pancreatic cancer treatment RASONQUE, reflecting roughly five weeks of U.S. sales and treatment of …

RVMD −2.5% todayRead at source ↗
● Seeking AlphaNov 4, 2026 · 20:34 ET
Revolution Medicines, Inc. (RVMD) Q3 2026 Earnings Call Transcript

Revolution Medicines, Inc. (RVMD) Q3 2026 Earnings Call Transcript…

RVMD −2.5% todayRead at source ↗
● Zacks Investment ResearchNov 4, 2026 · 18:16 ET
Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Beats Revenue Estimates

Revolution Medicines, Inc. (RVMD) came out with a quarterly loss of $1.9 per share versus the Zacks Consensus Estimate of a loss of $2.34. This compares to a loss of $1.61 per share a year ago.…

RVMD −2.5% todayRead at source ↗
● GlobeNewsWireNov 4, 2026 · 16:02 ETCOMPANY'S OWN WORDS
Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

Received U.S. FDA approval and launched RASONQUE® (daraxonrasib) for adult patients with metastatic pancreatic cancer who have received at least one prior systemic therapy or who are not candidates for multiagent systemi…

RVMD −2.5% todayRead at source ↗
● The Motley FoolOct 29, 2026 · 04:44 ET
Could Revolution Medicines Be a Millionaire-Maker Stock?

Revolution Medicines' stock has soared over 9x in three years. This success has been driven by excitement about the company's cancer drug, Rasonque.…

RVMD −2.5% todayRead at source ↗
● Defense WorldOct 28, 2026 · 04:06 ET
Revolution Medicines, Inc. $RVMD Holdings Cut by Citizens Financial Group Inc. RI

Citizens Financial Group Inc. RI cut its holdings in shares of Revolution Medicines, Inc. (NASDAQ: RVMD) by 92.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange …

RVMD −2.5% todayRead at source ↗
● The Motley FoolOct 27, 2026 · 17:41 ET
Billionaire Stanley Druckenmiller Added to Revolution Medicines Before Its FDA Win. Is the Stock Still a Buy After a 134% Run?

Stanley Druckenmiller's Duquesne Family Office increased its stake in Revolution Medicines during the second quarter. The biotech earned approval for an innovative medicine for pancreatic cancer in the third quarter.…

RVMD −2.5% todayRead at source ↗
● GlobeNewsWireOct 27, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Revolution Medicines to Participate in November 2026 Investor Conferences

REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for …

RVMD −2.5% todayRead at source ↗
● GlobeNewsWireOct 23, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026

REDWOOD CITY, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for …

RVMD −2.5% todayRead at source ↗
● GlobeNewsWireOct 21, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026

REDWOOD CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for …

RVMD −2.5% todayRead at source ↗
● GlobeNewsWireOct 20, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer

REDWOOD CITY, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for …

RVMD −2.5% todayRead at source ↗
● GlobeNewsWireOct 15, 2026 · 09:45 ETCOMPANY'S OWN WORDS
Revolution Medicines' RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer

Recommendation based on results from Phase 3 RASolute 302 trial, which demonstrated a 60% reduction in risk of death compared with chemotherapy in the overall study population with statistically significant and clinicall…

RVMD −2.5% todayRead at source ↗
● GlobeNewsWireOct 5, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer

REDWOOD CITY, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for …

RVMD −2.5% todayRead at source ↗
● GlobeNewsWireSep 14, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer

REDWOOD CITY, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for…

RVMD −2.5% todayRead at source ↗
● GlobeNewsWireSep 2, 2026 · 17:50 ET
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for…

RVMD −2.5% todayRead at source ↗

No upcoming events in the feeds.

NVDA31−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just RVMD · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.